SESSION TITLE: COPD Diagnosis and Evaluation Posters II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: The aims of the study: To study the correlation of ICFS as clinical indicator in COPD patients with severity, risk of hospitalization and duration of hospital stay.
METHODS: We study 56 patients attending assessment clinics during hospitalization and 85 patients during outpatient visits. Both questionnaire and physiologic data were collected. The correlations, multiple linear regressions, ANOVA and Cox proportional hazard models/negative binomial regressions were used.
RESULTS: Mean of ICFS in outpatients was 47.73 . Five sub scale mean values of feelings of fatigue, vigor, impact on concetration, on energy and daily acitivity were 64.42, 63.94, 27.72, 46.74, 47.73 respectively. Mean ICFS in hospitalized patients and sub scale mean values were 56.34, 67.29, 69.64, 49.71, 39.91, 55.10 respectively. Mean ICFS according to A, B, C, D stages of COPD patients were 44.54, 46.09, 51.76, 57.36 respectively. According to the ICFS values one patient had ICFS between 20 - 30, five patients 31 - 40, nine patientes 41 - 50, fifteen patients 51 - 60, fourteen patients 61 - 70, and six patients >70. The mean ICFS for day staying 1-7, 7-10, 10-15, >15 days was 46.45, 58.35, 60.28 and 67.65 respectively.
CONCLUSIONS: A significant relationship exist between ICFS values and COPD severity. ICFS values predict hospitalization risk and length of stay. ICFS must be another important instrument in predicting the severity and treatment strategy of COPD.
CLINICAL IMPLICATIONS: During the evaluation of severity of COPD exacerbations and treatment approach we have to measure and consider the ICFS which is a safe instrument in correct treatment of COPD exacerbations
DISCLOSURE: The following authors have nothing to disclose: Juli Gjerazi, Eritjan Tashi, Sofiela Telo, Arben Tanka, Edlira Ndreu, Esmeralda Nushi, Dhimitraq Argjiri, Eugerta Dilka, Elenka Shehu, Mirela Tabaku, Perlat Kapisyzi
No Product/Research Disclosure Information